.Pharmacolibrary.Drugs.C_CardiovascularSystem.C09C_AngiotensinIiReceptorBlockersArbsPlain.C09CA04_Irbesartan.Irbesartan .Pharmacolibrary.Drugs.C_CardiovascularSystem.C09C_AngiotensinIiReceptorBlockersArbsPlain.C09CA04_Irbesartan.Irbesartan| name: | Irbesartan |
| ATC code: | C09CA04 | route: | oral |
| n-compartments | 2 |
Irbesartan is an angiotensin II receptor blocker (ARB) used for the treatment of hypertension and diabetic nephropathy in type 2 diabetes. It is approved and currently used in clinical practice as an oral antihypertensive agent, typically as monotherapy or in combination with other antihypertensive drugs.
Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose.
Marino, MR, & Vachharajani, NN (2002). Pharmacokinetics of irbesartan are not altered in special populations. Journal of cardiovascular pharmacology 40(1) 112–122. DOI:10.1097/00005344-200207000-00014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12072584
Karatza, E, & Karalis, V (2020). Delay differential equations for the description of Irbesartan pharmacokinetics: A population approach to model absorption complexities leading to dual peaks. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 153 105498–None. DOI:10.1016/j.ejps.2020.105498 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32736091
Choi, CI, et al., & Lee, SY (2012). CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. European journal of clinical pharmacology 68(2) 149–154. DOI:10.1007/s00228-011-1098-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21842338